Skip to main content
. Author manuscript; available in PMC: 2018 May 15.
Published in final edited form as: J Immunol. 2017 Mar 31;198(10):3857–3868. doi: 10.4049/jimmunol.1601851

Figure 7. CD137 deficiency does not alter diabetes development in NOD mice transgenically expressing TCRs of the NY8.3 clonal type.

Figure 7

(A) Thymi from 6–7 week-old NOD.NY8.3 and NOD.Tnfrsf9−/−.NY8.3 female mice were analyzed for IGRP206-214 specific double-positive (DP) and CD8 single-positive (SP) thymocytes. Representative flow cytometry profiles for each strain are shown (left and middle panels). The results are summarized in the right panels. Each symbol represents one mouse. **P < 0.01 by Mann-Whitney test. (B) Spleens from 6–7 week-old NOD.NY8.3 and NOD.Tnfrsf9−/−.NY8.3 female mice were analyzed for IGRP206-214 specific CD8 T cells. Representative flow cytometry profiles for each strain are shown (left and middle panels). The results are summarized in the right panels. Each symbol represents one mouse. (C) T1D incidence study of NOD.NY8.3 and NOD.Tnfrsf9−/−.NY8.3 female mice. T1D development was monitored weekly using urine glucose strips with onset defined by two consecutive readings of > 250 mg/dl. Diabetes development is not significantly different between NOD.NY8.3 and NOD.Tnfrsf9−/−.NY8.3 mice.